Sun Pharmaceutical Industries Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sun Pharmaceutical Industries Ltd.
After seeing a spike in demand due to the coronavirus pandemic in Q1, with a corresponding dip in Q2, the generics industry has largely seen single-digit drops in net revenues in the third quarter of 2020. Meanwhile, the Indian pharma market has seen recovery after facing a challenging coronavirus-induced slump in the first two quarters of 2020.
Scrip takes a look at the key trends that could play out in 2021 to shape the trajectory of Indian drug makers, including evolving dynamics in the US under a new president. Thorny India-China relations will add a layer of complexity, while firms may also want to look beyond the chief information officers as they ramp up digital engagement.
Most roads led to India in 2020 when it came to deals to expand access to COVID-19 therapies, but the challenging year also saw significant private equity interest and there are expectations of more action ahead in the new year.
Aurobindo expects revenues from injectables to increase to $650m-$700m over the next three years as its Vizag plant gets commissioned in a year’s time. Apart from seeking organic growth, the company is keeping an eye out for acquisitions in emerging markets, though big-ticket M&A is ruled out.
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Aditya Acquisition Company ltd
- Caraco Pharmaceutical Laboratories, Ltd.
- DUSA Pharmaceuticals, Inc.
- InSite Vision, Inc.
- JSC Biosintez
- Ocular Technologies
- Pola Pharma Inc.
- Ranbaxy Laboratories Limited
- Ranbaxy Solus
- Solus Care
- Sun Ophthalmics
- Sun Pharma Global FZE